Product Description
Mechanisms of Action: Vitamin B6 Analogue
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: Chile | China | Colombia | Dominican Republic | Ecuador | Germany | Hong Kong | India | Indonesia | Ireland | Italy | Jordan | Mexico | Pakistan | Peru | Portugal | Romania | Russia | Turkey | Venezuela
Approved Indications: None
Known Adverse Events: None
Company: Hannover Medical School
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Tic Disorders|Depressive Disorder|Schizophrenia|Dementia|Psychophysiologic Disorders
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
GAP | P3 |
Terminated |
Schizophrenia|Depressive Disorder|Tic Disorders|Dementia|Psychophysiologic Disorders |
2017-06-28 |